cervical cancer rapid diagnostic test / HPV
Aptima HPV assay
for cervical cancer
The Aptima HPV assay offers a unique screening approach by targeting high-risk human papillomavirus (HPV) mRNA from the E6/E7 oncogenes. The Aptima HPV assay offers the same excellent sensitivity and improved specificity as compared to DNA-based tests.
HPV is responsible for more than 99% of all cervical cancers, which is one of the most common types of cancer affecting women throughout the world.1-3
The Aptima HPV assay identifies high-risk HPV infections by targeting E6/E7 mRNA.4 Studies show that targeting E6/E7 mRNA identifies the presence and activity of a high-risk HPV infection.5,6 The Aptima HPV assay represents the next generation in cervical cancer screening - allowing clinicians to deliver maximum benefits to patients, while minimizing potential harm.